Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.61 |
| ▸ | FEN1 | P39748 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9478990 | 0.84 | ERCC5 (0.71) | ALDH1A1LMNAHPGDPTPN1ERCC5 | |
| SCHEMBL23389159 | 0.83 | ALDH1A1 (0.60) | ALDH1A1LMNAHPGDPTPN1ERCC5 | |
| SCHEMBL8337079 | 0.83 | KDM4E (0.60) | ALDH1A1LMNAHPGDPTPN1ERCC5 | |
| SCHEMBL15498719 | 0.83 | ERCC5 (0.61) | ALDH1A1LMNAHPGDPTPN1ERCC5 | |
| Hydrochloric Acid SCHEMBL23389229 | 0.82 | ALDH1A1 (0.59) | ALDH1A1LMNAHPGDPTPN1ERCC5 | |
| SCHEMBL10750999 | 0.81 | ALDH1A1 (0.65) | ALDH1A1LMNAHPGDPTPN1ERCC5 | |
| SCHEMBL7118702 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNAHPGDPTPN1ERCC5 | |
| SCHEMBL25003140 | 0.81 | MAPT (0.57) | ALDH1A1HPGDKDM4EMAPTHTR1A | |
| SCHEMBL11826852 | 0.80 | ALDH1A1 (0.63) | ALDH1A1LMNAHPGDPTPN1ERCC5 | |
| SCHEMBL23389161 | 0.80 | ALDH1A1 (0.60) | ALDH1A1LMNAHPGDPTPN1ERCC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335420-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-10-10 | — | — | US | disclosed |
| EP-4382101-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118076347-A | N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same | 欧罗法玛实验室股份公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023010192-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023010192-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | disclosed |
| US-4643996-A | 5-phenyl-2-furoic acid hydrazides | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1987-02-17 | — | — | US | disclosed |
| US-4134893-A | Compound 2[5-(4-chlorophenyl)-2-furanyl]-5-mercapto-1,3,4-oxadiazole potassium salt is useful as an antifungal agent | MORTON-NORWICH PRODUCTS, INC. (US) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335420-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV 1.7 AND/OR NAV 1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME AND KITS | SCN1A, SCN1B, CACNA1B | ALDH1A1 429/4885LMNA 857/4885HPGD 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.